Skip to main content

Table 8 Doses and dosing intervals for the most commonly used BPs in pediatrics

From: Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

Drug Administration Dose
Pamidronate
(2nd generation)
Intravenous (dilute in 100-250 ml physiological saline solution, in 3–4 hours) <  1 year: 0. 5 mg/kg every 2 months
1–2 years: 0. 25-0. 5 mg/kg/day 3 days every 3 months
2–3 years: 0.375–0.75 mg/kg/day 3 days every 3 months
>  3 years: 0. 5–1 mg/kg/day 3 days every 4 months
Maximum dose: 60 mg/dose and 11. 5 mg/kg/year
Neridronate
(3rd generation)
Intravenous (dilute in 200–250 ml physiological saline solution, in 3 hours) 1–2 mg/kg/day every 3–4 months
Zolendronate
(3rd generation)
Intravenous (dilute in 50 ml physiological saline solution, in 30-45 min) 0.0125–0.05 mg/kg every 6–12 months (maximum dose 4 mg)
Alendronate
(2nd generation)
Oral 1–2 mg/kg/week
<  40 kg: 5 mg/day or 35 mg/week
>  40 kg: 10 mg/day or 70 mg/week
Maximum dose: 70 mg/week
Risendronate
(3rd generation)
Oral 15 mg/week (<  40 kg); 30 mg/week (> 40 kg)
Maximum dose: 30 mg/week